Definitions of Common Terminologies Used in Nuclear Medicine

  • Dibya Prakash


The term electromagnetic radiation or electromagnetic waves refers to energy in the form of oscillating electric and magnetic fields. Individual packets of electromagnetic radiation are referred to as photons. Photons with energy greater than 100 eV are classified as X-rays or gamma rays. Lower-energy photons may be in the range of ultraviolet light, infrared, visible light, radar waves, or radio and television waves. The unit of energy used to describe these electromagnetic waves or radiations is the electron volt (eV). One electron volt is defined as the kinetic energy of an electron accelerated through a potential difference of 1 V (1 eV = 1.6 × 10−19 J or 1.6 × 10−12 erg).


Cervical Cancer Percutaneous Coronary Intervention Human Papilloma Virus Lower Esophageal Sphincter Iodine Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Radioactive decay accessed from website
  2. 2.
    Patterson NR, George J. Graves’ disease in our own words. Cocoa Beach, US: Blue Note Publications; 2002. ISBN 1-878398-20-2.Google Scholar
  3. 3.
    Iglesias P, Dévora O, García J, Tajada P, García-Arévalo C, Díez JJ. Severe hyperthyroidism: aetiology, clinical features and treatment outcome. Clin Endocrinol (Oxf). 2009;72(4):551–7.CrossRefGoogle Scholar
  4. 4.
    Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358(24):2594–605.PubMedCrossRefGoogle Scholar
  5. 5.
    Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hørding M, Perrild H, Waldemar G. Impaired health-related quality of life in Grave’s disease. A prospective study. Eur J Endocrinol. 2004;151(5):549–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Watt T, Groenvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154(4):501–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Bunevicius R, Prange AJ. Psychiatric manifestations of Graves’ hyperthyroidism: pathophysiology and treatment options. CNS Drugs. 2006;20(11):897–909.PubMedCrossRefGoogle Scholar
  9. 9.
    Thorofare NJ. The clinical and pathological relationship of simple and exophthalmic goiter. Am J Med Sci 1913;146:790–5. Transactions of the Association of American Physicians, Philadelphia, 1928, 43:159.Google Scholar
  10. 10.
    Anu Bhalla D, Orlander PR. Toxic nodular goitre clinical presentation. Accessed 18 Mar 14.
  11. 11.
    Biswas SK, Jahan N, Rahman KBMA. Radioiodine (131i) therapy for thyrotoxicosis patients and their outcome: experience at Center for Nuclear Medicine & Ultrasound, Barisal. J Bangladesh Coll Physicians Surg. 2008;26(2):75.Google Scholar
  12. 12.
    Thyroiditis. 2005. American Thyroid Association. 13 Mar 2008. 15 Oct 2010.
  13. 13.
    Thyroiditis. 2005. American Thyroid Association. 15 Oct 2010.
  14. 14.
    Thyroiditis. 2007. Familydoctor.Org. American Academy of Family Physicians. 9 Mar 2008.Google Scholar
  15. 15.
    Hashimoto’s thyroiditis. 2003. ECureMe.Com. 15 Mar 2008.Google Scholar
  16. 16.
    Hashimoto’s disease. Health encyclopedia diseases and conditions. 2008. USA Today. 09 Mar 2008.Google Scholar
  17. 17.
  18. 18.
    American College of Radiology practice guideline for the performance of scrotal scintigraphy, Revised 2004 (Res. 31f) Effective 10/1/04, p. 545–547.Google Scholar
  19. 19.
    Avascular necrosis accessed from website on 14 Aug 2012.
  20. 20.
    Chao Y, Wang S, Chu H, Chang W, Hsieh T. Investigation of alcohol metabolizing enzyme genes in Chinese alcoholics with avascular necrosis of hip joint, pancreatitis and cirrhosis of the liver (free full text). Alcohol Alcohol. 2003;38(5):431–6. doi: 10.1093/alcalc/agg106. ISSN 0735–0414. PMID 12915519.PubMedCrossRefGoogle Scholar
  21. 21.
    Juéry P. Avascular necrosis after a steroid injection (free full text). Can Med Assoc J. 2007;176(6):814. doi: 10.1503/cmaj.1060165. ISSN 0820–3946. PMC 1808528. PMID 17353545.CrossRefGoogle Scholar
  22. 22.
    Baksi D. Treatment of post-traumatic avascular necrosis of the femoral head by multiple drilling and muscle-pedicle bone grafting. Preliminary report. J Bone Joint Surg Br. 1983;65(3):268–73. ISSN 0301-620X. PMID 6341373.PubMedGoogle Scholar
  23. 23.
    Lee C, Hansen H. Post-traumatic avascular necrosis of the humeral head in displaced proximal humeral fractures. J Trauma. 1981;21(9):788–91. doi: 10.1097/00005373-198109000-00006. ISSN 0022–5282. PMID 7277543.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang L, Kang J, Xue H. Distribution of lesions in the head and neck of the humerus and the femur in dysbaric osteonecrosis (free full text). Undersea Biomed Res. 1990;17(4):353–8. ISSN 0093–5387. PMID 2396333.PubMedGoogle Scholar
  25. 25.
    Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006;73(5):500–7. doi: 10.1016/j.jbspin.2006.01.025. ISSN 1297-319X. PMID 16931094.PubMedCrossRefGoogle Scholar
  26. 26.
    Laroche M. Intraosseous circulation from physiology to disease. Joint Bone Spine. 2002;69(3):262–9. doi: 10.1016/S1297-319X(02)00391-3. ISSN 1297-319X. PMID 12102272.PubMedCrossRefGoogle Scholar
  27. 27.
    Dannemann C, Grätz K, Riener M, Zwahlen R. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007;40(4):828–34. doi: 10.1016/j.bone.2006.11.023. ISSN 8756–3282. PMID 17236837.PubMedCrossRefGoogle Scholar
  28. 28.
    Martí-Carvajal A, Dunlop R, Agreda-Perez L. Treatment for avascular necrosis of bone in people with sickle cell disease. In: Martí-Carvajal, Arturo J, editors. Cochrane Database Syst Rev (Online). 2004;(4):CD004344. doi: 10.1002/14651858.CD004344.pub2. PMID 15495103.
  29. 29.
  30. 30.
    Day S, Ostrum R, Chao E, Rubin C, Aro H, Einhorn T. Bone injury, regeneration and repair. In: Buckwalter JA, Einhorn TA, Simon SR, editors. Orthopaedic basic science: biology and biomechanics of the musculoskeletal system. Rosemont: American Academy of Orthopaedic Surgeons; 2000. p. 372–99. OCLC 42969533. ISBN 0-89203-177-8.Google Scholar
  31. 31.
    Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJL. Cancer incidence, mortality and survival by site for 14 regions of the world. Global programme on evidence for health policy discussion paper no. 13. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.Google Scholar
  32. 32.
    Parham P. The immune system. New York: Garland Science; 2005. p. 414. ISBN 0-8153-4093-1.Google Scholar
  33. 33.
    Hellman S, Mauch PM, editors. Hodgkin’s disease. Chapter 1. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 5. ISBN 0-7817-1502-4.Google Scholar
  34. 34.
    Swerdlow SH, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Oxford, UK: Oxford University Press; 2008. ISBN 978-92-832-2431-0.Google Scholar
  35. 35.
    Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.PubMedCrossRefGoogle Scholar
  36. 36.
    Klein CA. Cancer. The metastasis cascade. Science. 2008;321(5897). doi: 10.1126/science.1164853. PMID 18818347.
  37. 37.
    Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Metastatic cancer accessed from the site on 18 Mar 14.
  39. 39.
    Don X. Nguyen, Joan Massagué. Genetic determinants of cancer metastasis. Nature.
  40. 40.
    Goldraich NP, Goldraich IH. Update on dimercaptosuccinic acid renal scanning in children with urinary tract infection. Pediatr Nephrol. 1995;9(2):221–6; discussion 227.PubMedCrossRefGoogle Scholar
  41. 41.
    Gordon I. Indications for 99mtechnetium dimercapto-succinic acid scan in children. J Urol. 1987;137(3):464–7.PubMedGoogle Scholar
  42. 42.
    Cardiovascular (coronary artery disease, hypertension and lipid trials) from website on 18 Mar 14.
  43. 43.
    Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339(3):173–81.PubMedCrossRefGoogle Scholar
  44. 44.
    Kosuge M, Kimura K, Ishikawa T, et al. Differences between men and women in terms of clinical features of ST-segment elevation acute myocardial infarction. Circ J. 2006;70(3):222–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis. 2011;104(3):178–88.PubMedCrossRefGoogle Scholar
  46. 46.
    Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain (PDF). Eur Heart J. 2002;23(15):1153–76.PubMedCrossRefGoogle Scholar
  47. 47.
    Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010;56(4):254–63.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Connor RE, Brady W, Brooks SC, et al. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S787–817.PubMedCrossRefGoogle Scholar
  49. 49.
    Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–45.PubMedCrossRefGoogle Scholar
  50. 50.
    Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.PubMedCrossRefGoogle Scholar
  51. 51.
    Ainsworth Barbara E, Haskell William L, Herrmann Stephen D, Meckes N, Bassett DR, Tudor-Locke C, Greer JL, Vezina J, et al. 2011 compendium of physical activities. Med Sci Sports Exerc. 2011;43(8):1575–81.PubMedCrossRefGoogle Scholar
  52. 52.
    Metabolic equivalent accessed from website
  53. 53.
    Park W, Vaezi M. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol. 2005;100(6):1404–14.PubMedCrossRefGoogle Scholar
  54. 54.
    Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut. 2001;49(1):145–51.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Pandolfino JE, Kahrilas PJ. AGA technical review on the clinical use of esophageal manometry. Gastroenterology. 2005;128(1):209–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Spiess AE, Kahrilas PJ. Treating achalasia: from whalebone to laparoscope. JAMA. 1998;280(7):638–42.PubMedCrossRefGoogle Scholar
  57. 57.
    Lake JM, Wong RK. Review article: the management of achalasia – a comparison of different treatment modalities. Aliment Pharmacol Ther. 2006;24(6):909–18.PubMedCrossRefGoogle Scholar
  58. 58.
    Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology. 2010;139(2):369–74.PubMedCrossRefGoogle Scholar
  59. 59.
    Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006;24(3):475–92.PubMedCrossRefGoogle Scholar
  60. 60.
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94(6):1434–42.PubMedCrossRefGoogle Scholar
  61. 61.
    Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006;7(10):956–60.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Yamaoka Y. Helicobacter pylori: molecular genetics and cellular biology. Poole, UK: Horizon Scientific Press; 2008. ISBN 1-904455-31-X.Google Scholar
  63. 63.
    Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97. PMID 11218379.PubMedCrossRefGoogle Scholar
  64. 64.
    Boyanova L, editor. Helicobacter pylori. Poole, UK: Horizon Scientific Press; 2011. ISBN 978-1-904455-84-4.Google Scholar
  65. 65.
    Butcher GP. Gastroenterology: an illustrated colour text. Philadelphia, PA: Elsevier Health Sciences; 2003. p. 25. ISBN 0-443-06215-3.Google Scholar
  66. 66.
    Ryan K. Sherris medical microbiology. New York: McGraw-Hill Medical; 2010. p. 573 and 576. ISBN 978-0-07-160402-4.Google Scholar
  67. 67.
    Elsayes KM, Menias CO, Harvin HJ, Francis IR. Imaging manifestations of Meckel’s diverticulum. AJR Am J Roentgenol. 2007;189(1):81–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Meckel JF. Über die Divertikel am Darmkanal. Archiv für die Physiologie, Halle. 1809;9:421–53.Google Scholar
  69. 69.
    Moore KL, Persaud TVN, Torchia MG. The developing human: clinically oriented embryology. 9th ed. Philadelphia: Elsevier/Saunders; 2013.Google Scholar
  70. 70.
    Mattei P. Fundamentals of pediatric surgery. New York: Springer Science + Business Media, LLC; 2011.CrossRefGoogle Scholar
  71. 71.
    Tutuian R, Castell D. Esophageal motility disorders (distal esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter): modern management. Curr Treat Options Gastroenterol. 2006;9(4):283–94.PubMedCrossRefGoogle Scholar
  72. 72.
    Fadil H, Borazanci A, Haddou EAB, Yahyaoui M, Korniychuk E, Jaffe SL, Minagar A. Early onset dementia. Int Rev Neurobiol. 2009;84:245–62. ISBN 978-0-12-374833-1.PubMedCrossRefGoogle Scholar
  73. 73.
    Swaminathan N. How to save your brain. Psychol Today. 2012;45:74–9.Google Scholar
  74. 74.
    Lake, CR. Schizophrenia is a misdiagnosis: implications for the DSM-5 and the ICD-11. 2012; XXVIII, p 28. Springer; 2012 edition, published at Springer Science+Business Media, LLC 2012. ISBN 978-1-4614-1870-2. doi: 10.1007/978-1-4614-1870-2.
  75. 75.
    Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257–66.PubMedCrossRefGoogle Scholar
  76. 76.
    Epilepsy, Fact sheet N°999, October 2012 published by World Health Organisation on website under sub title ‘Key facts’. Accessed 21 Mar 14.
  77. 77.
    Fisher R, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–2.PubMedCrossRefGoogle Scholar
  78. 78.
    Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–30.PubMedCrossRefGoogle Scholar
  79. 79.
    Holmes TR, Browne GL. Handbook of epilepsy. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. ISBN 9780781773973.Google Scholar
  80. 80.
    Elaine W, Cascino GD, Gidal BE, Goodkin HP. Wyllie’s treatment of epilepsy: principles and practice. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. ISBN 9781582559377.Google Scholar
  81. 81.
    Cascino GD. Epilepsy: contemporary perspectives on evaluation and treatment. Mayo Clin Proc. 1994;69:1199–211.PubMedCrossRefGoogle Scholar
  82. 82.
    Engel Jr J. Surgery for seizures. N Engl J Med. 1996;334(10):647–52.PubMedCrossRefGoogle Scholar
  83. 83.
    Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218–28.PubMedCrossRefGoogle Scholar
  84. 84.
    Kremer B. Clinical neurology of Huntington’s disease. In: Bates G, Harper P, Jones L, editors. Huntington’s disease. 3rd ed. Oxford: Oxford University Press; 2002. p. 28–53. ISBN 0-19-851060-8.Google Scholar
  85. 85.
    Wagle AC, Wagle SA, Marková IS, Berrios GE. Psychiatric morbidity in Huntington’s disease. Neurol Psychiatry Brain Res. 2000;8:5–16.Google Scholar
  86. 86.
    Frank S, Jankovic J. Advances in the pharmacological management of Huntington’s disease. Drugs. 2010;70(5):561–71.PubMedCrossRefGoogle Scholar
  87. 87.
    Sariego J. Breast cancer in the young patient. Am Surg. 2010;76(12):1397–401.PubMedGoogle Scholar
  88. 88.
    Breast Cancer published by Northern Cancer Institute on website Data accessed on 21 Mar 14.
  89. 89.
    Florescu A, Amir E, Bouganim N, Clemons M. Immune therapy for breast cancer in 2010—hype or hope? Curr Oncol. 2011;18(1):e9–18.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Breast Cancer as a Multifactorial Disease: Interaction of Genetics, Life Stage, and the Environment. Published by Society of Toxicology on 06/28/2013 on website Accessed 21 Mar 14.
  91. 91.
    Walters S, Davies K, Maringe C, Coleman MP, Rachet B, Gordon E, Jakomis N. Cancer survival in England Patients diagnosed 2004–2008, followed up to 2009 page 1. Published on 21 Apr 2011in collaboration between the London School of Hygiene and Tropical Medicine (LSHTM) and the Cancer Analysis Team at the Office for National Statistics.Google Scholar
  92. 92.
    Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins basic pathology. 8th ed. Saunders/Elsevier; 2007. p. 718–721. ISBN 978-1-4160-2973-1.Google Scholar
  93. 93.
    Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician. 2000;61(5):1369–76.PubMedGoogle Scholar
  94. 94.
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116(5):1167–73.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Colorectal Cancer Incidence, Mortality and Prevalence Worldwide in 2008 — Summary. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10; 2010.Google Scholar
  97. 97.
    Kumar V, Fausto N, Abbas A, editors. Robbins & Cotran pathologic basis of disease. 7th ed. Philadelphia: Saunders; 2003. p. 914–7. ISBN 978-0-7216-0187-8.Google Scholar
  98. 98.
    Hepatocellular carcinoma accessed from website
  99. 99.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.PubMedGoogle Scholar
  100. 100.
    Hellman S. Brief consideration of Thomas Hodgkin and his times. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, editors. Hodgkin lymphoma. 2nd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 3–6. ISBN 0-7817-6422-X.Google Scholar
  101. 101.
    Hodgkin T. On some morbid experiences of the absorbent glands and spleen. Med Chir Trans. 1832;17:69–97.Google Scholar
  102. 102.
    Surveillance, Epidemiology, and End Results (SEER) Program (
  103. 103.
    Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph. 1872;4(2):265–73.CrossRefGoogle Scholar
  104. 104.
    Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;265:1865–9.CrossRefGoogle Scholar
  105. 105.
    Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN. Awareness of Kaposi’s sarcoma-associated herpesvirus among men who have sex with men. Sex Transm Dis. 2008;35(12):1011–4.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62(2):357–68. p. 375–6, p. 381–2.PubMedGoogle Scholar
  107. 107.
    Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRefGoogle Scholar
  108. 108.
    Kanavy HE, Gerstenblith MR. Ultraviolet radiation and melanoma. Semin Cutan Med Surg. 2011;30(4):222–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.PubMedCrossRefGoogle Scholar
  110. 110.
    Jost LM. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. Ann Oncol. 2003;14(7):1012–3.PubMedCrossRefGoogle Scholar
  111. 111.
    Lucas R, McMichael T, Smith W, Armstrong B. (PDF) Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental burden of disease series. 13. World Health Organization, Geneva, Switzerland; 2006. ISBN 92-4-159440-3.Google Scholar
  112. 112.
    Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1–16.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Non-Small Cell Lung Cancer Treatment Under subheading General Information about Non-Small Cell Lung Cancer (NSCLC), Health Professional Version. Published by U.S. National Library of Medicine – The World’s Largest Medical Library on website Accessed 21 Mar 14.
  114. 114.
    Express News Service, Early Diagnosis of Ovarian Cancer Only Hope under subheading Symptoms of ovarian cancer creep on silently, it’s important to stay alert. Published on Dec 11, 2013 by The New Indian Express.Google Scholar
  115. 115.
    Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol. 2008;622:79–87.PubMedCrossRefGoogle Scholar
  116. 116.
    Piek JMJ. Hereditary serous ovarian carcinogenesis, a hypothesis. Doctoral Theses — Medicine. Amsterdam: Vrije Universiteit; 2004.Google Scholar
  117. 117.
    Lister S. Urine test could speed treatment of prostate cancer. London: The Sunday Times; 2009.Google Scholar
  118. 118.
    Hayes-Lattin B, Nichols CR. Testicular cancer: a prototypic tumor of young adults. Semin Oncol. 2009;36(5):432–8.PubMedCentralPubMedCrossRefGoogle Scholar
  119. 119.
  120. 120.
    Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299(6):672–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  • Dibya Prakash
    • 1
  1. 1.Department of Nuclear MedicineINHS, AsviniMumbaiIndia

Personalised recommendations